GLP-1 medications cause rapid weight loss — but some of that loss is muscle. Here is what the clinical data shows about muscle loss on semaglutide and the evidence-based strategies to minimize it.
The STEP 1 extension trial shows participants regained a mean of 11.6 percentage points of body weight in the year after stopping semaglutide. Here is what the research says and what it means for long-term treatment.
Ozempic and Wegovy both contain semaglutide. But they are FDA-approved for different conditions, at different doses, and covered differently by insurance. Here is exactly what sets them apart.
Nausea is the most common side effect of semaglutide — affecting up to 44% of users in clinical trials. Here is why it happens and what actually helps.
PCOS affects 8-13% of women and is tightly linked to insulin resistance. Here is what peer-reviewed research actually shows about GLP-1 medications and PCOS symptoms.
Wegovy pill (FDA-approved Dec 2025) vs the injection — actual clinical trial numbers: STEP 1 trial shows 14.9% average weight loss for injection, OASIS 4 shows 13.6% for the pill.
Food noise is the near-constant mental chatter about food that plagues millions of people. Here is what it is, why GLP-1 medications like semaglutide silence it, and the brain science behind it.
